| P2093 | author name string | Kieran Sheahan | |
| | Éanna J Ryan | |
| | Ben Creavin | |
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| | Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer | Q24614511 |
| | Correlation of immunohistochemical mismatch repair protein status between colorectal carcinoma endoscopic biopsy and resection specimens | Q50118977 |
| | Multicenter Evaluation of Rectal cancer ReImaging pOst Neoadjuvant (MERRION) Therapy. | Q51205146 |
| | Loss of MHC class II expression is associated with a decrease of tumor-infiltrating T cells and an increase of metastatic potential of colorectal cancer: immunohistological and histopathological analyses as compared with normal colonic mucosa and ad | Q52141881 |
| | The prognostic significance of postchemoradiotherapy high-resolution MRI and histopathology detected extramural venous invasion in rectal cancer. | Q52838823 |
| | Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. | Q52938786 |
| | Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6). | Q53059376 |
| | Pulmonary recurrence predominates after combined modality therapy for rectal cancer: an original retrospective study. | Q53158504 |
| | MRI Detection of Extramural Venous Invasion in Rectal Cancer: Correlation With Histopathology Using Elastin Stain. | Q53159438 |
| | The immune molecular landscape of the B7 and TNFR immunoregulatory ligand-receptor families in head and neck cancer: A comprehensive overview and the immunotherapeutic implications. | Q53359622 |
| | Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? | Q54198857 |
| | Hereditary colorectal cancer syndromes: American Society of Clinical Oncology clinical practice guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology clinical practice guidelines. | Q54271215 |
| | Age at onset should be a major criterion for subclassification of colorectal cancer. | Q54399530 |
| | The clinical features of rectal cancers with high-frequency microsatellite instability (MSI-H) in Japanese males. | Q54696194 |
| | Colorectal cancer | Q55924124 |
| | Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer | Q56895579 |
| | Molecular origins of cancer: Molecular basis of colorectal cancer | Q24617331 |
| | Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field | Q24620628 |
| | Comprehensive molecular characterization of human colon and rectal cancer | Q24630415 |
| | CpG island methylator phenotype in colorectal cancer | Q24672170 |
| | Starved and Asphyxiated: How Can CD8(+) T Cells within a Tumor Microenvironment Prevent Tumor Progression | Q26767514 |
| | Immune Checkpoint Blockade in Cancer Therapy | Q26830509 |
| | Towards the introduction of the 'Immunoscore' in the classification of malignant tumours | Q27026489 |
| | Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial | Q27853380 |
| | A genetic model for colorectal tumorigenesis | Q27860582 |
| | Genetic instabilities in human cancers | Q28131826 |
| | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 |
| | Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer | Q28298328 |
| | The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase | Q28512554 |
| | Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status | Q29619648 |
| | Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines | Q29620526 |
| | HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression | Q33690070 |
| | Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers | Q33699887 |
| | Rectal cancer level significantly affects rates and patterns of distant metastases among rectal cancer patients post curative-intent surgery without neoadjuvant therapy | Q33942156 |
| | Microsatellite instability and survival in rectal cancer | Q33954707 |
| | Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study | Q34102606 |
| | Differences in short-term outcomes among patients undergoing IPAA with or without preoperative radiation: a National Surgical Quality Improvement Program analysis. | Q34164201 |
| | Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. | Q34169310 |
| | Rectal cancer in hereditary nonpolyposis colorectal cancer | Q34263782 |
| | Preoperative versus postoperative chemoradiotherapy for rectal cancer | Q34552041 |
| | Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. | Q34557699 |
| | The chromosomal instability pathway in colon cancer | Q34570062 |
| | Perineural invasion is an independent predictor of outcome in colorectal cancer. | Q34611646 |
| | Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years | Q34637749 |
| | Familial colorectal cancer, beyond Lynch syndrome | Q34655489 |
| | The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints | Q34943776 |
| | Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies | Q35050076 |
| | International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study | Q56932170 |
| | Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer | Q56932490 |
| | Fusion kinases identified by genomic analyses of sporadic microsatellite instability-high colorectal cancers | Q57045127 |
| | Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer | Q57455374 |
| | MRI-detected extramural vascular invasion is an independent prognostic factor for synchronous metastasis in patients with rectal cancer | Q59115806 |
| | Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study | Q59883523 |
| | The Severity of Neural Invasion Is a Crucial Prognostic Factor in Rectal Cancer Independent of Neoadjuvant Radiochemotherapy | Q60056786 |
| | The TME Trial After a Median Follow-up of 6 Years | Q61481329 |
| | Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium “Care for CMMR-D” (C4CMMR-D) | Q62978114 |
| | The prognostic value of tumor-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: a systematic review and meta-analysis | Q64279907 |
| | Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location. | Q64898611 |
| | A new prognostic classification of rectal cancer | Q69899908 |
| | Microsatellite instability is rare in rectal carcinomas and signifies hereditary cancer | Q73112583 |
| | Long-term results of the Lyons R90-01 randomized trial of preoperative radiotherapy with delayed surgery and its effect on sphincter-saving surgery in rectal cancer | Q73775338 |
| | Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab | Q80704669 |
| | The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer | Q82445247 |
| | Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer | Q84454983 |
| | Effect of Multidisciplinary Cancer Conference on Treatment Plan for Patients With Primary Rectal Cancer | Q85641158 |
| | How reliable is immunohistochemical staining for DNA mismatch repair proteins performed after neoadjuvant chemoradiation? | Q87645153 |
| | Left-Sided Dominance of Early-Onset Colorectal Cancers: A Rationale for Screening Flexible Sigmoidoscopy in the Young | Q88715264 |
| | Prognostic value and characteristics of N1c colorectal cancer | Q89077864 |
| | Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial: Dutch results | Q89763695 |
| | Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018 | Q90903275 |
| | Genetics of rectal cancer and novel therapies: primer for radiologists | Q91904795 |
| | Systematic review of outcomes after total neoadjuvant therapy for locally advanced rectal cancer | Q91911899 |
| | Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer | Q92737659 |
| | The 2019 WHO classification of tumours of the digestive system | Q92748103 |
| | Mechanisms of immunogenicity in colorectal cancer | Q92875307 |
| | Meta-analysis of the effect of extending the interval after long-course chemoradiotherapy before surgery in locally advanced rectal cancer | Q92875334 |
| | Systemic inflammatory response predicts oncological outcomes in patients undergoing elective surgery for mismatch repair-deficient colorectal cancer | Q93143962 |
| | NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial) | Q96020568 |
| | Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer | Q35463514 |
| | HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. | Q35659589 |
| | Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers | Q35810106 |
| | RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer | Q35911017 |
| | Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer | Q35929864 |
| | Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome | Q35998356 |
| | Neoadjuvant treatment response as an early response indicator for patients with rectal cancer | Q36058487 |
| | KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases | Q36071767 |
| | The consensus molecular subtypes of colorectal cancer | Q36258187 |
| | Molecular classification and correlates in colorectal cancer | Q36329300 |
| | Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. | Q36348179 |
| | Classification of colorectal cancer based on correlation of clinical, morphological and molecular features | Q36699559 |
| | Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). | Q36746989 |
| | Biallelic mutation of MSH2 in primary human cells is associated with sensitivity to irradiation and altered RAD51 foci kinetics. | Q37004544 |
| | What is the role for the circumferential margin in the modern treatment of rectal cancer? | Q37053363 |
| | Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment | Q37268974 |
| | Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer | Q37328638 |
| | Identification of Lynch syndrome among patients with colorectal cancer | Q37416078 |
| | Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer | Q37459563 |
| | Restaging of Rectal Cancer with MR Imaging after Concurrent Chemotherapy and Radiation Therapy | Q37708985 |
| | Can we predict pathologic complete response before surgery for locally advanced rectal cancer treated with preoperative chemoradiation therapy? | Q37955677 |
| | Developments in the assessment of venous invasion in colorectal cancer: implications for future practice and patient outcome | Q37992400 |
| | Radiotherapy response in microsatellite instability related rectal cancer | Q38088639 |
| | Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis | Q38117128 |
| | Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis | Q38152337 |
| | Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. | Q38511709 |
| | American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Lynch Syndrome | Q38557619 |
| | Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review | Q38623990 |
| | MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial. | Q38692801 |
| | Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. | Q38707904 |
| | Tailored Treatment Strategy for Locally Advanced Rectal Carcinoma Based on the Tumor Response to Induction Chemotherapy: Preliminary Results of the French Phase II Multicenter GRECCAR4 Trial | Q38736429 |
| | Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. | Q38947246 |
| | BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies | Q39347386 |
| | The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing | Q39426336 |
| | Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial | Q39748379 |
| | KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy | Q39884524 |
| | Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. | Q40243706 |
| | The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. | Q40446318 |
| | DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics. | Q41024077 |
| | Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study | Q41155680 |
| | Lymphovascular invasion: a comprehensive appraisal in colon and rectal adenocarcinoma | Q41257141 |
| | Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression | Q41590802 |
| | The immune score as a new possible approach for the classification of cancer | Q42539190 |
| | Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer | Q43285217 |
| | Quality of life after ileal pouch-anal anastomosis: an evaluation of diet and other factors using the Cleveland Global Quality of Life instrument. | Q43350505 |
| | High risk of rectal cancer and of metachronous colorectal cancer in probands of families fulfilling the Amsterdam criteria | Q43774739 |
| | Peritumoral deposits as an adverse prognostic indicator of colorectal cancer | Q43966913 |
| | Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. | Q44045712 |
| | Risk of colonic neoplasia after proctectomy for rectal cancer in hereditary nonpolyposis colorectal cancer. | Q44234196 |
| | PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection | Q44941056 |
| | Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. | Q45071422 |
| | Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. | Q46031466 |
| | Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. | Q46067914 |
| | Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles | Q46335149 |
| | The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. | Q46373510 |
| | Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. | Q46722869 |
| | Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study | Q47556085 |
| | Clinicopathological, genomic and immunological factors in colorectal cancer prognosis | Q47728264 |
| | The correlation of microsatellite instability and tumor-infiltrating lymphocytes in hereditary non-polyposis colorectal cancer (HNPCC) and sporadic colorectal cancers: the significance of different types of lymphocyte infiltration | Q47809942 |
| | Meta-analysis of the impact of surgical approach on the grade of mesorectal excision in rectal cancer | Q48170193 |
| | Magnetic Resonance Imaging-Detected Extramural Venous Invasion in Rectal Cancer before and after Preoperative Chemoradiotherapy: Diagnostic Performance and Prognostic Significance. | Q48276189 |
| | Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer | Q49887005 |
| | Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer | Q50116991 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 1369 | |
| P577 | publication date | 2020-08-14 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm | |
| P478 | volume | 10 | |